Status:
COMPLETED
A Trial of Aprepitant For Prevention of Post-Endoscopic Retrograde Cholangiopancreatography (ERCP) Pancreatitis
Lead Sponsor:
Duke University
Collaborating Sponsors:
Merck Sharp & Dohme LLC
Conditions:
Pancreatitis
Eligibility:
All Genders
18-60 years
Phase:
NA
Brief Summary
The purpose of this study is to determine if giving Aprepitant 4 hours before and for two days after ERCP decreases the risk of developing pancreatitis after ERCP.
Detailed Description
This study involves taking a drug Aprepitant by mouth 4 hours before the ERCP and once a day for two days after the ERCP, in an attempt to reduce the risk of pancreatitis caused by ERCP. Pancreatitis,...
Eligibility Criteria
Inclusion
- Patients selected for the study will be those undergoing ERCP who are at high risk for development of post-ERCP pancreatitis
- patients expected to undergo a sphincterotomy
- patients with suspected sphincter of oddi dysfunction
- patients with a known history in the past of post-ERCP pancreatitis
- patients less than 60 years of age
Exclusion
- active pancreatitis
- if they are pregnant
- known adverse reaction to aprepitant
Key Trial Info
Start Date :
August 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2012
Estimated Enrollment :
73 Patients enrolled
Trial Details
Trial ID
NCT00736073
Start Date
August 1 2007
End Date
November 1 2012
Last Update
June 22 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Duke University Medical Center
Durham, North Carolina, United States, 27710